Effects of ipilimumab on absolute and relative eosinophil counts and co-relationship with incidence of immune-related adverse events in patients with malignant melanoma.

Trial Profile

Effects of ipilimumab on absolute and relative eosinophil counts and co-relationship with incidence of immune-related adverse events in patients with malignant melanoma.

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Jul 2014

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Biomarker; Pharmacodynamics
  • Most Recent Events

    • 22 Jul 2014 New trial record
    • 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top